Sophoricoside from sophora japonica L. is efficacious as monotherapy or in combination with lenvatinib in hepatocellular carcinoma via targeting EGFR

Sophora japonica L. is a commonly used traditional Chinese medicine. Sophoricoside (Sop), the isoflavone glycoside obtained in Sophora japonica L., is demonstrated with various pharmacological activities, such as anticancer, anti-inflammation, and immunosuppression. To data, there is a lack of comprehensive...

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Original Article Share on Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCAuthors: Pasi A. Jänne, M.D., Ph.D., David Planchard, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Ying Liu, M.D., Natalia Valdiviezo, M.D., Tae Min Kim,...

Uromodulin alleviates fibrosis in acute kidney injury to chronic kidney disease transition by reducing EGFR

AbstractBackground Uromodulin has been speculated as a protective factor for acute kidney injury (AKI) and chronic kidney disease (CKD), possibly based on the uromodulin-mediated cross-talk between thick ascending limbs and proximal tubules. Here, we explored the roles of uromodulin in...

Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells

AbstractBackground Tyrosine kinase inhibitors (TKIs) are widely used to treat non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, long-term use frequently leads to drug resistance. These resistant cells often exhibit distinct phenotypes from their parental...